| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1994.12.12.2687 |
| P698 | PubMed publication ID | 7989945 |
| P2093 | author name string | V De Lisi | |
| F Di Costanzo | |||
| G Cocconi | |||
| M Bella | |||
| M Soldani | |||
| R Algeri | |||
| G Luppi | |||
| C Rodinò | |||
| S Zironi | |||
| B Mazzocchi | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| fluorouracil | Q238512 | ||
| P304 | page(s) | 2687-2693 | |
| P577 | publication date | 1994-12-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research | |
| P478 | volume | 12 |
| Q92105271 | A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer |
| Q44180988 | A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer |
| Q33403949 | Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma |
| Q37191102 | Challenge for a better combination with basic evidence |
| Q24236634 | Chemotherapy for advanced gastric cancer |
| Q24244040 | Chemotherapy for advanced gastric cancer |
| Q38604012 | Chemotherapy for advanced gastric cancer. |
| Q36398226 | Chemotherapy for gastric cancer. |
| Q37191094 | Chemotherapy for metastatic disease: review from JCOG trials |
| Q61868286 | Chemotherapy of oesophago-gastric cancer |
| Q33328092 | Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: the SAKK experience. Swiss Group for Clinical Cancer Research (SAKK). |
| Q77337899 | Clinical trials for advanced gastrointestinal cancers in Japan. Japan Clinical Oncology Group Gastrointestinal Oncology Study Group |
| Q35097713 | Curative treatment of gastric cancer: towards a multidisciplinary approach? |
| Q33332444 | Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). |
| Q54571851 | Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. |
| Q52864641 | Epirubicin, cisplatin and oral UFT with leucovorin ('ECU'): a phase I-II study in patients with advanced upper gastrointestinal tract cancer. |
| Q38794776 | Esophagogastric Adenocarcinoma: Is More Chemotherapy Better? |
| Q52216230 | Ethics and practice: alternative designs for phase III randomized clinical trials. |
| Q43264239 | Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study |
| Q40585334 | Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study |
| Q33327923 | Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). |
| Q33376701 | Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study |
| Q42285544 | Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial |
| Q35936039 | Palliative chemotherapy for advanced gastric cancer |
| Q33341045 | Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer |
| Q35181033 | Phase II Study of S-1 Monotherapy as a First-line, Combination Therapy of S-1 plus Cisplatin as a Second-line, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma: Phase II Study of S-1, S-1 plus Cis |
| Q83969749 | Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: a novel, safe, and active regimen |
| Q33361500 | Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. |
| Q34852173 | Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis |
| Q37636574 | Pre-operative chemotherapy for gastric cancer |
| Q43421738 | Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab |
| Q92723576 | Randomization in clinical studies |
| Q53604465 | Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. |
| Q40032426 | Randomized phase III trial of cisplatin, epirubicin, leucovorin, 5-fluorouracil (PELF) combination versus 5-fluorouracil alone as adjuvant chemotherapy in curative resected stage III gastric cancer |
| Q37815444 | Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer |
| Q41044387 | Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis |
| Q35095365 | Status of treatment for advanced gastric carcinoma |
| Q37923311 | Systemic therapy for advanced gastric cancer: a clinical practice guideline |
| Q36292847 | Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer |
Search more.